Summary
With the acquisition of Evalve, Abbott will position itself on the lead for structural heart disease.
Analysis
Mitral regurgitation is the most prevalent valvular conditions; patients need serial monitoring and, eventually, surgery should the ventricular function decline and/or the left ventricle enlarge. Having a minimally invasive way to fix the mitral valve opens a potential for new business. With the acquisition of Evalve, Abbott will position itself on the lead for structural heart disease. Already a leader on the coronary market, Abbott will strengthen its position as provider of comprehensive percutaneous services.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
